Stock Analiz

Ascendis Pharma A (ASND) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Ascendis Pharma A’s revenue went from $5M in fiscal 2016 to $846M in fiscal 2025, growth of about 77.4% a year.

Net income in fiscal 2025 was -$268M, a net margin of -31.7%; the best year in this period was 2016 with -$72M.

Over the twelve months to September 30, 2026, revenue was $1.3B and net income $966M.

Revenue, profit and cash flow by year

Revenue
2016: $5M162017: $2M172018: $12M182019: $15M192020: $9M202021: $9M212022: $55M222023: $295M232024: $378M242025: $846M25$846M
Net income
2016: -$72M162017: -$149M172018: -$149M182019: -$245M192020: -$514M202021: -$434M212022: -$622M222023: -$532M232024: -$393M242025: -$268M25-$268M
Free cash flow
2016: -$64M20162017: -$115M20172018: -$162M20182019: -$203M20192020: -$358M20202021: -$500M20212022: -$544M20222023: -$519M2023-$519M
EPS (diluted)
2016: $-1.10162017: $-2.26172018: $-2.26182019: $-3.72192020: $-7.80202021: $-6.59212022: $-9.44222023: $-8.07232024: $-5.96242025: $-4.0725$-4.07

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.3B$846M$378M$295M$55M$9M$9M$15M$12M$2M$5M
Gross profit—$735M$332M$246M$42M$5M$9M$15M———
Operating income—-$160M-$290M-$503M-$599M-$512M-$406M-$255M-$177M-$134M-$77M
Net income$966M-$268M-$393M-$532M-$622M-$434M-$514M-$245M-$149M-$149M-$72M
EPS (diluted)$14.78$-4.07$-5.96$-8.07$-9.44$-6.59$-7.80$-3.72$-2.26$-2.26$-1.10
R&D———————————
Revenue growth—+124.0%+28.2%+440.0%+519.6%+3.2%−43.2%+24.0%+560.3%−62.2%−45.1%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$591M$63M-$318M-$516M-$529M-$473M-$333M-$198M-$159M-$114M-$63M
Capital spending-$19M——-$3M-$15M-$27M-$24M-$6M-$3M-$1M-$708353
Free cash flow$572M——-$519M-$544M-$500M-$358M-$203M-$162M-$115M-$64M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks—$20M$0$0$112M$24M—————
Stock-based pay—$137M$99M$74M$68M$76M$65M$42M$23M$12M$8M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$724M$581M$433M$474M$505M$717M$672M$318M$234M$190M
Debt—$957M$855M$696M$426M$119M—————
Equity—-$191M-$110M-$161M$281M$1.0B$1.0B$671M$321M$225M$186M
Total assets—$1.5B$1.2B$912M$1.2B$1.2B$1.2B$760M$365M$253M$200M
Shares (diluted)65M66M66M66M66M66M66M66M66M66M66M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—86.8%87.8%83.4%76.3%54.7%100.0%100.0%———
Operating margin—-18.9%-76.7%-170.8%-1097.9%-5808.6%-4755.1%-1695.1%-1462.6%-7290.3%-1583.2%
Net margin72.9%-31.7%-104.0%-180.5%-1139.6%-4931.6%-6025.5%-1630.0%-1229.5%-8097.8%-1487.3%
FCF margin43.1%——-176.1%-997.0%-5674.4%-4191.1%-1354.0%-1336.8%-6277.1%-1321.1%
ROIC—-16.5%-30.7%-74.3%-67.0%-45.7%-39.4%-37.9%-55.1%-59.4%-41.1%
ROE—140.1%357.7%330.4%-221.5%-43.4%-50.0%-36.5%-46.5%-66.2%-38.8%

Frequently asked questions

What is Ascendis Pharma A’s annual revenue?

$846M in fiscal 2025 and $1.3B over the twelve months to September 30, 2026.

How much profit does Ascendis Pharma A make?

Net income was -$268M in fiscal 2025 (net margin -31.7%).

Is Ascendis Pharma A’s revenue growing?

Yes: revenue rose 124.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.